Opinion|Videos|December 11, 2024
The Real-World Logistics of CAR T Therapy: Financial and Practical Considerations
Panelists discuss how a patient and their medical team collaborated to evaluate the differences between ide-cel and cilta-cel CAR T therapies to make an informed treatment decision.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please walk us through the process of shared decision-making between you and your health care team. How did you decide between ide-cel and cilta-cel?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.